What are the side effects of BPC-157?

Why there are no rates on this page

Side-effect rates come from systematic collection during controlled trials: a defined population, a defined exposure, and adverse events recorded whether or not anyone thought to look for them. BPC-157 has no completed trial of that kind. Any percentage attached to it would therefore be built from what people volunteered about themselves, and that source has a specific blind spot — it captures what a person noticed and connected to the compound, which excludes anything too gradual, too quiet, or too rare to stand out against ordinary life. Other pages on this site carry rate tables because named trials produced them. This one does not, and borrowing the format without the evidence behind it would be the more misleading choice.

What “no toxic dose identified” actually establishes

The animal toxicology record is genuinely unusual: across roughly thirty years of study, researchers have not identified a toxic dose in the tested species. That is worth reporting plainly. What it establishes is that acute toxicity did not appear in those animals at the doses examined. What it does not establish is a human safety profile, because the questions that matter most — effects over years, effects in people with existing disease, interactions — are not the questions an acute animal toxicology study asks.

Absence of a finding is also sensitive to what was measured. A study designed to detect acute toxicity is not designed to detect a slow one, and reading its silence as an all-clear extends the result past what it covered.

What users report

The commonly reported effects are mild and local: injection-site redness or irritation that resolves within hours, occasional mild dizziness in the early period, and inconsistent reports of mild headache. These come from user report rather than trial collection, which is why they are described here as reports rather than rates. The consistent thread is that no systemic effect appears reliably enough across sources to characterise.

The angiogenesis question, stated precisely

Part of BPC-157's proposed mechanism involves promoting new blood-vessel growth, and that raises a theoretical question about whether it could support the growth of an existing tumour. The published animal and human literature contains no reports of this occurring. It also contains no study designed to look for it — the research measured wound healing and tissue repair, not malignancy risk. So the question is open rather than answered, and it is open in both directions: the absence of reports is not evidence of absence when nothing was measuring.

What the regulatory position adds, and what it does not

BPC-157 was placed in Category 2 of the FDA's bulk drug substances list in 2023 — the significant-safety-concern category, which bars compounding pharmacies from preparing it. Its subsequent history is procedural rather than substantive: it was technically removed from Category 2 when the original nominators withdrew, then renominated through a different pathway. Removal from Category 2 does not authorise compounding and does not place a substance in Category 1. The category placement reflects a regulatory judgement made largely on the absence of adequate safety data, so it is better read as another statement of that absence than as an independent finding about the molecule.

What none of this covers

Everything above concerns the molecule. A vial sold on the research market raises separate questions — identity, purity, and what else is in it — that no amount of pharmacology speaks to, and that are the more immediate variable where no approval process stands behind the contents.